Product Information
AUVELITY ER 45-105 MG TABLET is a brand product labeled by Axsome Therapeutics, Inc., priced at $19.8977 per EA under NDC 81968004530. Its NADAC has been published 189 times since Feb 22, 2023.
FDA first approved this application on Aug 18, 2022.
Strength
105; 45 mg/1; mg/1
Manufacturer
Axsome Therapeutics, Inc.NDC
81968004530
Classification
Brand
Dosage Form
TABLET, MULTILAYER, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA215430FDA Approved
8/18/2022
On Market Since
8/18/2022
Pharmacological Classes
Price Statistics
The NADAC for AUVELITY ER 45-105 MG TABLET has been published 189 times since Feb 22, 2023, and over the history we have for it it has risen 19.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.8977 per EA |
|---|---|
| All-time high | $19.8977 (Sep 30, 2026) |
| All-time low | $16.7145 (Feb 22, 2023) |
| 52-week high | $19.8977 |
| 52-week low | $18.7566 |
| Median price | $17.7490 |
| Average price | $18.2861 |
| Largest weekly change | +6.0% (Oct 25, 2023) |
| Weeks tracked | 189 |
| Tracking since | Feb 22, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Axsome Therapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dextromethorphan hydrobromide, bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AUVELITY ER 45-105 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AUVELITY ER 45-105 MG TABLET, manufactured by Axsome Therapeutics, Inc., is $19.8977 per EA (NDC 81968004530), effective Sep 30, 2026.
How has the price of AUVELITY ER 45-105 MG TABLET changed over time?
Over the history we have for it, the NADAC for AUVELITY ER 45-105 MG TABLET has risen 19.0%. It has been tracked across 189 weekly CMS publications since Feb 22, 2023.
What are the highest and lowest recorded NADAC prices for AUVELITY ER 45-105 MG TABLET?
Since Feb 22, 2023, the NADAC for AUVELITY ER 45-105 MG TABLET has ranged from a low of $16.7145 (Feb 22, 2023) to a high of $19.8977 (Sep 30, 2026), with a median of $17.7490 per EA.
Are there cheaper alternatives to AUVELITY ER 45-105 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as AUVELITY ER 45-105 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures AUVELITY ER 45-105 MG TABLET?
AUVELITY ER 45-105 MG TABLET (NDC 81968004530) is labeled by Axsome Therapeutics, Inc., and CMS classifies it as a brand product.